COVID-19 vaccine: A global race

Abstract

The emergence of the new coronavirus SARS-CoV-2, at the end of 2019, triggered the worst pandemic of the last century, called COVID-19. Unlike SARS-CoV-1, which developed as an epidemic in 1996 but was limited to Asia, the new SARS-CoV-2 spread rapidly to millions of people worldwide, with a high mortality rate. Deciphering the structure of the viral S and SARS-CoV genome-2 allowed the identification of targets for vaccination, the most important being the viral protein S. The development of -COVID-19 vaccines is based on use innovative biotechnologies, some even experimental. Experience in vaccines SARS-CoV-1-MERS-CoV and may be useful for designing bad vaccine by emerging virus of SARS-CoV-2. Developing a vaccine anti-COVID-19 efficient, safe and accessible in the shortest possible time, remains the biggest challenge overall, in the race to limit pandemic today.